Advances in B7-H3 as a Therapeutic Target in Advanced Solid Tumors: Rapid Response From Paris

Author(s)/Faculty: Melissa L. Johnson, MD; Charu Aggarwal, MD, MPH; Robert L. Ferris, MD, PhD
Release Date: 9/30/2022Expiration Date: 9/29/2023
Credit Type: CMENumber of Credits: 0.75
Content Type: LectureProvider:
Immuno-oncology (IO) continues to evolve as investigators seek therapeutic approaches that improve response rates, survival benefits, and durability of response in advanced cancer. B7-H3 is an immunomodulatory transmembrane glycoprotein that is overexpressed by several solid tumors, including cancers of the lung, breast, brain, kidney, and prostate. By targeting this novel immune checkpoint, anti–B7-H3 therapy may improve outcomes for patients with advanced solid tumors. Education is needed to keep practitioners apprised of the ever-evolving IO landscape. This Rapid Response educational activity will provide highlights on the latest developments in B7-H3–targeted therapy. Faculty will describe the emerging role of B7-H3 as a biomarker and therapeutic target, as well as review the latest data on investigational antibody-drug conjugates, antibody therapies, and chimeric antigen receptor T cell approaches.